Intelligent Medicine Acquisition Corp. Announces Closing of Upsized $207,000,000 Initial Public Offering

Rhea-AI Summary

Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) has successfully closed its upsized initial public offering of 20,700,000 units at $10.00 per unit. This includes 2,700,000 units purchased by Cantor Fitzgerald through an over-allotment option. The units began trading on the Nasdaq on November 5, 2021. Each unit consists of one share of common stock and one-half of a redeemable warrant, with whole warrants priced at $11.50 per share. The Company aims to pursue business combinations primarily in the life sciences sector, targeting firms that leverage AI and big data for drug discovery.

Positive

• Successfully raised $207 million through the upsized IPO.
• Strategically focused on life science companies utilizing AI for drug discovery, offering potential for growth.

Negative

• None.

BETHESDA, Md.--(BUSINESS WIRE)-- Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) (the “Company” or “Intelligent Medicine”) today announced that it closed its upsized initial public offering of 20,700,000 units at a price of $10.00 per unit, including 2,700,000 units purchased by Cantor Fitzgerald & Co. (“Cantor”) pursuant to the over-allotment option granted to Cantor in its role as sole book running manager for the offering. The units began trading on the Nasdaq Global Market (NASDAQ) under the ticker symbol “IQMDU” on November 5, 2021. Each unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder to purchase one share of common stock of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares and warrants are expected to be traded on NASDAQ under the symbols “IQMD” and “IQMDW,” respectively.

Intelligent Medicine was formed for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although the Company’s efforts to identify a prospective business combination opportunity will not be limited to a particular industry, it intends to focus on life science companies that are using artificial intelligence, machine learning and big data to power drug discovery.

The offering was made only by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, c/o Cantor Fitzgerald & Co., 499 Park Avenue, 5th Floor, New York, New York 10022, or by email at prospectus@cantor.com. Copies of the registration statements can also be accessed through the SEC’s website at www.sec.gov.

The registration statement relating to the securities became effective on November 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the Company’s plans with respect to the target industry for a potential business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the SEC. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006674/en/

Brian Ruby, ICR, brian.ruby@icrinc.com

Source: Intelligent Medicine Acquisition Corp.

FAQ

What was the price per unit for Intelligent Medicine Acquisition Corp's IPO?

The price per unit was $10.00.

How many units were offered in the IPO by Intelligent Medicine Acquisition Corp?

A total of 20,700,000 units were offered.

When did Intelligent Medicine Acquisition Corp start trading on Nasdaq?

The trading began on November 5, 2021.

What is the ticker symbol for Intelligent Medicine Acquisition Corp?

The ticker symbol is IQMDU.

What is the purpose of Intelligent Medicine Acquisition Corp's formation?

The Company was formed to pursue a merger, acquisition, or similar business combination with one or more businesses.